Clinical trials: Metastatic Invasive Breast Cancer
Breast Cancer, Metastatic Invasive Breast Cancer
Diagnostic Prediction Model for De Novo Metastatic Breast Cancer
The goal of this observational study is to create a tool to estimate the risk of macroscopic distant tumor spread in women with newly diagnosed breast cancer.
- Trial name
- NCT07752238
- Where
- Hungary
- Volunteers
- 925 people
- Sponsor
- Markusovszky University Teaching Hospital os County Vas
Breast Cancer, Chronic Myeloproliferative Disorders
Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation
RATIONALE: Antifungals such as ravuconazole may be effective in preventing fungal infections in patients undergoing chemotherapy and stem cell transplantation.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection
- Trial name
- NCT00064311
- Testing
- ravuconazole
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Carcinoma, Lobular
Diagnostic Performance of [18F]FES PET/CT for Axillary LN Metastasis in Invasive Lobular Carcinoma
This study aims to explore the diagnostic validity of [18F]FES PET/CT for the evaluation of axillary lymph node metastasis in patients with invasive lobular breast cancer having clinically suspected or confirmed axillary lymph…
- Trial name
- NCT05960201
- Testing
- [18F]fluoroestradiol (FES)
- Where
- South Korea
- Volunteers
- 23 people
- Sponsor
- Asan Medical Center
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Lobular Carcinoma
Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer
This phase I trial studies how well fluciclovine positron emission tomography (PET)/computed tomography (CT) and PSMA PET/CT work in helping doctors understand and classify invasive lobular breast cancer in patients with invasive…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Lobular Carcinoma, Metastatic Breast Lobular Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
- Trial name
- NCT04750473
- Testing
- Computed Tomography, Fluciclovine F18, Gallium Ga 68 Gozetotide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Emory University
Breast Cancer Stage I, Breast Cancer Stage II
Role of Triggering Receptor Expressed on Myeloid Cells (TREM-1) as a Novel Biomarker in Human Epidermal Growth Factor Receptor -2 (HER-2) Negative Breast Cancer: a Molecular and Clinical Study
Global cancer statistics by world region for the year 2022 estimated breast cancer the 2nd cause of new cancer cases (11.6%). (1) Approximately 80% of all breast cancers (BCs) are currently categorized as human epidermal growth…
- Conditions
- Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Invasive
- Trial name
- NCT06950671
- Where
- Egypt
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Rahma Esam Salama Esawi
Metastatic Invasive Lobular Carcinoma (mILC)
Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer
The goal of this study is to characterize early dynamic changes in ctDNA, which can aid in tailoring early therapy in patients with metastatic Invasive lobular carcinoma (ILC).
- Trial name
- LBC-Monitor (NCT06666439)
- Testing
- circulating tumor DNA (ctDNA)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Julia Foldi
Metastatic Breast Cancer
CRYO-TOUCH: Cryoablation of the Primary Breast Tumor in Metastatic Breast Cancer
Metastatic breast cancer remains an incurable disease for most patients. While surgical treatment of the primary breast tumor is commonly performed in localized breast cancer, its role in metastatic breast cancer remains…
- Trial name
- CRYO-TOUCH (NCT07676344)
- Testing
- Cryoablation, Patient-Reported Outcome Assessment
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Hospices Civils de Lyon
Synchronous Metastasized Breast Cancer, Circulating Tumor Cells
Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Primary Operation in synchronous metastasized invasive breast cancer to evaluate the use of local therapy
- Trial name
- POSYTIVE (NCT01015625)
- Testing
- Surgery, Surgery on Demand
- Where
- 14 sites in Austria
- Volunteers
- 90 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer
BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
This phase I trial studies the side effects and best dose of the PI3K inhibitor BYL719 when given together with letrozole in treating patients with hormone receptor-positive metastatic breast cancer.
- Conditions
- Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma, Progesterone Receptor-positive Breast Cancer
- Trial name
- NCT01791478
- Testing
- PI3K inhibitor BYL719, letrozole, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Male Breast Cancer, Recurrent Breast Cancer
Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer
This randomized phase I/II trial studies the side effects and best dose of vaccine therapy and to see how well it works when given together with 1-methyl-D-tryptophan (1-MT) in treating patients with metastatic breast cancer.
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT01042535
- Testing
- adenovirus-p53 transduced dendritic cell (DC) vaccine, 1-methyl-d-tryptophan, Laboratory biomarker analysis
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Resistant Breast Cancer, Non-metastatic Invasive Breast Cancer
Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast Cancer
This is a single-arm, prospective, non-randomized, feasibility study evaluating concurrent capecitabine-radiotherapy in participants with Resistant Breast Cancer.
- Trial name
- NCT03958721
- Testing
- Capecitabine, Radiotherapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- A Bapsi Chakravarthy, MD
Metastatic Breast Cancer, ER Positive Breast Cancer
To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer
This is a multi-center biomarkers study aiming to prospectively collect biological samples from patients with ER+ and HER2-negative metastatic breast cancer, who are candidate to first-line treatment with an aromatase inhibitor…
- Conditions
- Metastatic Breast Cancer, ER Positive Breast Cancer, HER2-negative Breast Cancer
- Trial name
- TIRESIAS (NCT04660435)
- Testing
- Thymidine kinase activity
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Fondazione Sandro Pitigliani
Breast Cancer, Neuroendocrine Tumors
Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients
Prospective phase 2a clinical trial to demonstrate proof-of-concept for simultaneous hyperpolarized [1-13C]pyruvate and 18F-FDG for positron emission tomography (PET) and MRS (magnetic resonance spectroscopy) in a PET/MR scanner…
- Conditions
- Breast Cancer, Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Carcinoma Metastatic
- Trial name
- NCT05396118
- Testing
- 18F-FDG, Injection of hyperpolarized [1-13C]Pyruvate, PET/MR/MRS/MRSI scanning
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Estrogen Receptor Status, HER2/Neu Negative
Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer
This phase II trial studies how well alisertib with or without fulvestrant works in treating patients with endocrine-resistant breast cancer that has spread to other places in the body.
- Conditions
- Estrogen Receptor Status, HER2/Neu Negative, Invasive Breast Carcinoma, Postmenopausal
- Trial name
- NCT02860000
- Testing
- Alisertib, Fulvestrant, Laboratory Biomarker Analysis
- Where
- 8 sites in United States
- Volunteers
- 96 people
- Sponsor
- Mayo Clinic
Breast Cancer, Colorectal Cancer
Biological Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I trial to study the effectiveness of biological therapy in treating patients who have…
- Conditions
- Breast Cancer, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00004604
- Testing
- CEA RNA-pulsed DC cancer vaccine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Duke University
Invasive Breast Cancer
Radiomic Markers for Breast Cancer Metastasis and Treatment Response Using MRI
The primary aim of the study is to identify radiomic features as biomarkers of metastatic progression following primary therapy.
- Trial name
- NCT03709186
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sunnybrook Health Sciences Centre
Breast Neoplasms
Nodal Staging in Breast Cancer With MRL
The aim of this study is to examine the diagnostic performance of gadofosveset enhanced magnetic resonance imaging lymphography (MRL).
- Trial name
- NCT01609920
- Testing
- Gadofosveset enhanced MRL of axillary lymph nodes
- Where
- Netherlands
- Volunteers
- 97 people
- Sponsor
- Maastricht University Medical Center
Adenocarcinoma of the Breast
Lymph Fluid and Blood Collection for Identification of Novel Biomarkers
The objective of this study is to identify and validate metastasis protein markers in lymph collected from women with metastatic breast cancer.
- Trial name
- NCT01075607
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Indiana University
Breast Cancer
PD0332991/Paclitaxel in Advanced Breast Cancer
This study is a phase I, single arm, open-label trial of PD0332991 in combination with Paclitaxel in patients with Rb-expressing metastatic breast cancer.
- Trial name
- NCT01320592
- Testing
- PD0332991, Paclitaxel
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer, Metastatic Invasive Lobular Breast Cancer
Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET
This study is a pilot clinical imaging trial of a prospective, head-to-head comparison of 18F-Fibroblast Activation Protein Inhibitor (FAPI)-74 PET/CT versus standard-of-care 18F-Fluorodeoxyglucose (FDG) PET/CT in 15 patients…
- Trial name
- NCT07285993
- Testing
- 18F-FAPI-74, 18F-FDG, PET/CT
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Randy Yeh